Lung Adenocarcinoma — Trials

Lung Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

231 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 27
Ph III recruiting: 6
Growth YoY: —
Industry share: 13%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (28)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07169903	Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT(STAR012)	not yet recruiting	Phase 3	587	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	1	Sep 12, 2025	clinicaltrials
NCT06858410	Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma	not yet recruiting	Phase 3	36	Guangdong Association of Clinical TrialsOTHER	0